Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Kraslavas Aprinkis, Latvia Clinical Trials

A listing of Kraslavas Aprinkis, Latvia clinical trials actively recruiting patients volunteers.

RESULTS

Found (58810) clinical trials

Ruxolitinib (previously known as INCB018424 phosphate, INC424, ruxolitinib phosphate) is a novel, potent, and selective inhibitor of Janus kinase (JAK) 1 and JAK2 with modest to marked selectivity against tyrosine kinase 2 (TYK2) and JAK3, respectively. Ruxolitinib has been granted marketing authorisation approval for the treatment of myelofibrosis (MF) and ...

Phase

This trial is an open-label, single arm phase II study assessing the tolerability and anti-tumour activity of afatinib when given in combination with a fixed dose of pembrolizumab in patients with squamous NSCLC, who progressed during or after first line platinum-based standard therapy and had no prior treatment with an ...

Phase

Primary Objective: To compare efficacy of ruxolitinib versus anagrelide as measured by the proportion of subjects demonstrating platelet and white blood cell (WBC) control. Secondary Objectives: To evaluate the safety and tolerability of ruxolitinib compared with anagrelide in subjects with essential thrombocythemia (ET). To compare complete remission (CR) and partial ...

Phase

The purpose of this Phase 2 study is: To find out if the addition of nivolumab when given with veliparib in combination with platinum doublet chemotherapy extends the time your cancer is not getting worse compared to veliparib with platinum doublet chemotherapy alone. Platinum doublet chemotherapy is either carboplatin and ...

Phase N/A

The purpose of this research study is to see if nivolumab and ipilimumab in combination with chemotherapy is better at improving survival when compared to standard chemotherapy treatment. This study will also test the effectiveness (how well the drug works), safety, and tolerability of the nivolumab and ipilimumab combined with ...

Phase

The purpose of this research study is to evaluate the safety profile of rovalpituzumab tesirine on the heart’s electrical function in subjects with SCLC. The study also serves to determine if rovalpituzumab tesirine can be administered safely and if it is an effective treatment for subjects with SCLC

Phase N/A

Multi-center, prospective, single-arm, continued access study of the Optimizer Smart System with CCM therapy. All subjects will be followed until the PMA order has been issued by the FDA. The protocol is designed to collect adverse safety events, quality of life data and data needed for comparison with long term ...

Phase N/A

The primary objective is to show the benefit of SmartDelay™ in patients with a prolonged RV-LV interval.

Phase N/A

The proposed study utilizes a prospective, non-interventional, observational cohort study design to evaluate the necessary duration of monitoring following treatment with LEMTRADA and to further inform appropriate monitoring conditions. It will evaluate the long term safety profile, particularly the AESI incidence rates over time in RMS patients, to accomplish the ...

Phase N/A

To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.

Phase N/A